FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891413637> ?p ?o ?g. }

• W2891413637 endingPage "16829" @default.
• W2891413637 startingPage "16818" @default.
• W2891413637 abstract "Insulin and insulin-like growth factor 1 (IGF-1) are closely related hormones involved in the regulation of metabolism and growth. They elicit their functions through activation of tyrosine kinase–type receptors: insulin receptors (IR-A and IR-B) and IGF-1 receptor (IGF-1R). Despite similarity in primary and three-dimensional structures, insulin and IGF-1 bind the noncognate receptor with substantially reduced affinity. We prepared [d-HisB24, GlyB31, TyrB32]-insulin, which binds all three receptors with high affinity (251 or 338% binding affinity to IR-A respectively to IR-B relative to insulin and 12.4% binding affinity to IGF-1R relative to IGF-1). We prepared other modified insulins with the aim of explaining the versatility of [d-HisB24, GlyB31, TyrB32]-insulin. Through structural, activity, and kinetic studies of these insulin analogs, we concluded that the ability of [d-HisB24, GlyB31, TyrB32]-insulin to stimulate all three receptors is provided by structural changes caused by a reversed chirality at the B24 combined with the extension of the C terminus of the B chain by two extra residues. We assume that the structural changes allow the directing of the B chain C terminus to some extra interactions with the receptors. These unusual interactions lead to a decrease of dissociation rate from the IR and conversely enable easier association with IGF-1R. All of the structural changes were made at the hormones' Site 1, which is thought to interact with the Site 1 of the receptors. The results of the study suggest that merely modifications of Site 1 of the hormone are sufficient to change the receptor specificity of insulin. Insulin and insulin-like growth factor 1 (IGF-1) are closely related hormones involved in the regulation of metabolism and growth. They elicit their functions through activation of tyrosine kinase–type receptors: insulin receptors (IR-A and IR-B) and IGF-1 receptor (IGF-1R). Despite similarity in primary and three-dimensional structures, insulin and IGF-1 bind the noncognate receptor with substantially reduced affinity. We prepared [d-HisB24, GlyB31, TyrB32]-insulin, which binds all three receptors with high affinity (251 or 338% binding affinity to IR-A respectively to IR-B relative to insulin and 12.4% binding affinity to IGF-1R relative to IGF-1). We prepared other modified insulins with the aim of explaining the versatility of [d-HisB24, GlyB31, TyrB32]-insulin. Through structural, activity, and kinetic studies of these insulin analogs, we concluded that the ability of [d-HisB24, GlyB31, TyrB32]-insulin to stimulate all three receptors is provided by structural changes caused by a reversed chirality at the B24 combined with the extension of the C terminus of the B chain by two extra residues. We assume that the structural changes allow the directing of the B chain C terminus to some extra interactions with the receptors. These unusual interactions lead to a decrease of dissociation rate from the IR and conversely enable easier association with IGF-1R. All of the structural changes were made at the hormones' Site 1, which is thought to interact with the Site 1 of the receptors. The results of the study suggest that merely modifications of Site 1 of the hormone are sufficient to change the receptor specificity of insulin." @default.
• W2891413637 created "2018-09-27" @default.
• W2891413637 creator A5003313570 @default.
• W2891413637 creator A5004481123 @default.
• W2891413637 creator A5007064621 @default.
• W2891413637 creator A5011006755 @default.
• W2891413637 creator A5032341489 @default.
• W2891413637 creator A5036984210 @default.
• W2891413637 creator A5038803700 @default.
• W2891413637 creator A5054944892 @default.
• W2891413637 creator A5064220061 @default.
• W2891413637 creator A5079551434 @default.
• W2891413637 date "2018-10-01" @default.
• W2891413637 modified "2023-10-18" @default.
• W2891413637 title "A versatile insulin analog with high potency for both insulin and insulin-like growth factor 1 receptors: Structural implications for receptor binding" @default.
• W2891413637 cites W1541126533 @default.
• W2891413637 cites W1560164243 @default.
• W2891413637 cites W1566241360 @default.
• W2891413637 cites W1589509381 @default.
• W2891413637 cites W1590353710 @default.
• W2891413637 cites W1822043635 @default.
• W2891413637 cites W1964622466 @default.
• W2891413637 cites W1965143532 @default.
• W2891413637 cites W1967573365 @default.
• W2891413637 cites W1968816575 @default.
• W2891413637 cites W1971940467 @default.
• W2891413637 cites W1986536315 @default.
• W2891413637 cites W1993625949 @default.
• W2891413637 cites W1994563972 @default.
• W2891413637 cites W1997146974 @default.
• W2891413637 cites W1997287492 @default.
• W2891413637 cites W2001751915 @default.
• W2891413637 cites W2018026151 @default.
• W2891413637 cites W2020796391 @default.
• W2891413637 cites W2026415340 @default.
• W2891413637 cites W2053208884 @default.
• W2891413637 cites W2075197583 @default.
• W2891413637 cites W2078640994 @default.
• W2891413637 cites W2079659159 @default.
• W2891413637 cites W2080746623 @default.
• W2891413637 cites W2082427983 @default.
• W2891413637 cites W2099129157 @default.
• W2891413637 cites W2107372727 @default.
• W2891413637 cites W2112848560 @default.
• W2891413637 cites W2115572072 @default.
• W2891413637 cites W2121328410 @default.
• W2891413637 cites W2121558812 @default.
• W2891413637 cites W2157151585 @default.
• W2891413637 cites W2157707796 @default.
• W2891413637 cites W2171598944 @default.
• W2891413637 cites W2220237426 @default.
• W2891413637 cites W2342863747 @default.
• W2891413637 cites W2395426357 @default.
• W2891413637 cites W2715761994 @default.
• W2891413637 cites W2766586147 @default.
• W2891413637 cites W2769466932 @default.
• W2891413637 cites W2788776849 @default.
• W2891413637 cites W2789212851 @default.
• W2891413637 cites W2795393313 @default.
• W2891413637 doi "https://doi.org/10.1074/jbc.ra118.004852" @default.
• W2891413637 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6204900" @default.
• W2891413637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30213860" @default.
• W2891413637 hasPublicationYear "2018" @default.
• W2891413637 type Work @default.
• W2891413637 sameAs 2891413637 @default.
• W2891413637 citedByCount "5" @default.
• W2891413637 countsByYear W28914136372020 @default.
• W2891413637 countsByYear W28914136372022 @default.
• W2891413637 crossrefType "journal-article" @default.
• W2891413637 hasAuthorship W2891413637A5003313570 @default.
• W2891413637 hasAuthorship W2891413637A5004481123 @default.
• W2891413637 hasAuthorship W2891413637A5007064621 @default.
• W2891413637 hasAuthorship W2891413637A5011006755 @default.
• W2891413637 hasAuthorship W2891413637A5032341489 @default.
• W2891413637 hasAuthorship W2891413637A5036984210 @default.
• W2891413637 hasAuthorship W2891413637A5038803700 @default.
• W2891413637 hasAuthorship W2891413637A5054944892 @default.
• W2891413637 hasAuthorship W2891413637A5064220061 @default.
• W2891413637 hasAuthorship W2891413637A5079551434 @default.
• W2891413637 hasBestOaLocation W28914136371 @default.
• W2891413637 hasConcept C112446052 @default.
• W2891413637 hasConcept C126322002 @default.
• W2891413637 hasConcept C134018914 @default.
• W2891413637 hasConcept C139489369 @default.
• W2891413637 hasConcept C170493617 @default.
• W2891413637 hasConcept C185592680 @default.
• W2891413637 hasConcept C185967709 @default.
• W2891413637 hasConcept C2775960820 @default.
• W2891413637 hasConcept C2777391703 @default.
• W2891413637 hasConcept C2779306644 @default.
• W2891413637 hasConcept C2780689927 @default.
• W2891413637 hasConcept C55493867 @default.
• W2891413637 hasConcept C71315377 @default.
• W2891413637 hasConcept C71924100 @default.
• W2891413637 hasConcept C82183700 @default.
• W2891413637 hasConcept C86803240 @default.
• W2891413637 hasConceptScore W2891413637C112446052 @default.
• W2891413637 hasConceptScore W2891413637C126322002 @default.

• next